Raptor Pharmaceutical has submitted a new drug application (NDA) to the FDA for marketing approval of Cysteamine Bitartrate delayed-release capsules (RP103), to treat nephropathic cystinosis. Raptor has appealed for priority review of ...
Tags: clinical trial, pharmaceutical product, new drug application